Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
80,235,145
-
Total 13F shares
-
45,688,568
-
Share change
-
+2,209,550
-
Total reported value
-
$1,933,296,396
-
Put/Call ratio
-
11%
-
Price per share
-
$42.32
-
Number of holders
-
124
-
Value change
-
+$62,437,636
-
Number of buys
-
76
-
Number of sells
-
48
Institutional Holders of Kymera Therapeutics, Inc. - Common Stock (KYMR) as of Q1 2022
As of 31 Mar 2022,
Kymera Therapeutics, Inc. - Common Stock (KYMR) was held by
124 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
45,688,568 shares.
The largest 10 holders included
Atlas Venture Life Science Advisors, LLC, PRICE T ROWE ASSOCIATES INC /MD/, BVF INC/IL, BlackRock Inc., WELLINGTON MANAGEMENT GROUP LLP, VANGUARD GROUP INC, Redmile Group, LLC, BAKER BROS. ADVISORS LP, STATE STREET CORP, and FMR LLC.
This page lists
124
institutional shareholders reporting positions in this security
for the Q1 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.